Holen Sie sich die Stockscreener-App
45.25
2.13%
0.95
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com
Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus
Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance
Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus
Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily
Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC - Defense World
Bank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - Defense World
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94 - Defense World
Zacks Research Has Bullish Forecast for Exelixis Q2 Earnings - Defense World
Exelixis Escapes Cancer Drug Invalidity Bid At PTAB - Law360
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice - Yahoo Finance
Analyst Expectations For Exelixis's Future - Benzinga
Exelixis (EXEL) Sees Price Target Raised by B of A Securities | - GuruFocus
BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise
Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - MarketScreener
Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com
Stifel maintains hold rating on Exelixis stock, sets $38 target - Investing.com
Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia
Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Promising Growth Potential - DirectorsTalk Interviews
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia
Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):